The US FDA has agreed to the clinical trial design and conduct proposed by Jaguar Health for the evaluation of Canalevia-CA1 (crofelemer delayed-release tablets) for the treatment of CT-induced diarrhea (CID) in dogs. The company expects to receive the US FDA’s full approval based on this trial
Earlier in Dec 2021, Jaguar received the US FDA’s conditional approval for Canalevia-CA1 to treat CID in dogs. Later in Dec 2023, the conditional approval was renewed to a validity up until 21st Dec 2024
Canalevia-CA1 is an oral plant-based (canine-specific formulation of crofelemer) prescription product conditionally approved by the US FDA, received through the MUMS pathway
Ref: Jaguar Health | Image: Jaguar Health
Related News:- Jaguar Health’s Canalevia-CA1 Receives Conditional Approval Renewal from the US FDA for Chemotherapy-Induced Diarrhea in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
